Reduction of PGD2 to 11β-PGF2α correlated linearly with AKR1C3 protein expression in the cancer cell line panel, indicating that PGD2 reduction provides a measurable biomarker of AKR1C3 activity in cells. This evidence concerns the gene AKR1C3 and cancer.